Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | S. Murphy | M. Mercuri | N. Rost | S. Wiviott | C. Ruff | L. Grip | Scott B. Silverman | Cheryl Lowe | Naveen Deenadayalu | Joshua Betcher | A. Duggal | Jay Dave | M. Shi
[1] R. Giugliano,et al. Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice , 2014, American Journal of Cardiovascular Drugs.
[2] T. van der Poll,et al. Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System: Lessons From a Tick Salivary Protein , 2013, Circulation.
[3] P A Wolf,et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.
[4] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[5] R. Giugliano,et al. Edoxaban: Review of pharmacology and key phase I to III clinical trials. , 2014, Journal of cardiovascular pharmacology and therapeutics.
[6] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[7] R. Perera,et al. Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.
[8] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[9] D. Ward,et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study , 2008, Journal of thrombosis and haemostasis : JTH.
[10] D. Singer,et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. , 2004, Archives of internal medicine.
[11] S. Yusuf,et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.
[12] Nikhil Sharma,et al. Recovery of motor function after stroke. , 2012, Developmental psychobiology.
[13] B. Norrving,et al. Management and Prognostic Features of Intracerebral Hemorrhage During Anticoagulant Therapy: A Swedish Multicenter Study , 2001, Stroke.
[14] J. Rankin,et al. Cerebral Vascular Accidents in Patients over the Age of 60: I. General Considerations , 1957, Scottish medical journal.
[15] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[16] E. Antman,et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. , 2005, European heart journal.
[17] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[18] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[19] R. Beaglehole,et al. Recovery of motor function after stroke. , 1988, Stroke.
[20] R. Giugliano,et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. , 2007, Journal of the American College of Cardiology.
[21] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[22] Yuchiao Chang,et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.
[23] E. Hylek,et al. National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation , 2014, Circulation.
[24] J. Spertus,et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). , 2011, The American journal of cardiology.
[25] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[26] M. Rosenqvist,et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. , 2011, European heart journal.